ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Otsuka Holdings Co., Ltd.

  • 4,390.00 JPY
  • +12.00
  • +0.27%
  • Japan
    Aug 23, 2019
  • Ticker
    TKS(4578)
  • Prev. close
    4,378
  • Market cap (JPY)
    2,442.20B
  • Market cap (USD)
    22,900.31M
  • Shares
    557.83M

Business Summary

Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. It operates through the following businesses: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals business manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals business develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products business sells mineral water, food, and beverages. Its products include Bon Curry, Mannan Hikari, and ReSOLA. The Others business distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2018 JPYUSD
Revenue1,291.98B11,698.18M
Gross Profit850,149M7,697.63M
Operating income104,918M949.97M
Income before tax109,497M991.43M
Net income82,492M746.92M
EBITDA164,193M1,486.67M
Diluted EPS151.261.36
Dividends Per Share1000.90
Total Assets2,476.63B22,573.34M
Total liabilities744,366M6,784.54M
Total equity1,704.50B15,535.70M
Operating cash flow135,821M1,229.78M
Currency in JPYCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 1,632.39B 1,427.37B 1,195.74B 1,239.95B 1,291.98B
Gross Profit 1,135.04B 974,909M 789,415M 817,540M 850,149M
Operating income 262,036.67M 135,762M 84,435M 112,679M 104,918M
Income before tax 282,667.27M 137,929M 100,706M 103,712M 109,497M
Net income 193,130.16M 101,957M 92,563M 112,492M 82,492M
EBITDA 322,752.52M 194,918M 144,009M 174,914M 164,193M
Diluted EPS 356.43 188.15 170.70 206.99 151.26
Dividends Per Share 75 100 100 100 100
Total Assets 2,178.18B 2,575.28B 2,478.29B 2,480.25B 2,476.63B
Total liabilities 499,893M 847,907M 739,845M 658,303M 744,366M
Total equity 1,627.80B 1,698.46B 1,710.53B 1,793.27B 1,704.50B
Operating cash flow 88,535M 257,892M 142,004M 102,832M 135,821M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 15,421.76M 11,790.17M 11,004.58M 11,057.80M 11,698.18M
Gross Profit 10,723.18M 8,052.78M 7,265.07M 7,290.76M 7,697.63M
Operating income 2,475.54M 1,121.39M 777.06M 1,004.86M 949.97M
Income before tax 2,670.45M 1,139.29M 926.80M 924.89M 991.43M
Net income 1,824.56M 842.16M 851.86M 1,003.19M 746.92M
EBITDA 3,049.15M 1,610.03M 1,325.33M 1,559.87M 1,486.67M
Diluted EPS 3.36 1.55 1.57 1.84 1.36
Dividends Per Share 0.70 0.82 0.92 0.89 0.90
Total Assets 18,167.43M 21,408.03M 21,248.25M 22,017.36M 22,573.34M
Total liabilities 4,169.42M 7,048.56M 6,343.25M 5,843.79M 6,784.54M
Total equity 13,576.89M 14,119.15M 14,665.67M 15,919.02M 15,535.70M
Operating cash flow 836.41M 2,130.19M 1,306.87M 917.04M 1,229.78M

Valuation Measures

Dec 2018
PER29.51
ROA3.32%
ROE4.71%
Operating margin8.12%
Profit margin6.38%

Key executives

  • President, CEO & Representative Director: Tatsuo Higuchi
  • Manager-Finance & Accounting: Toshifumi Arai
  • Vice President-Global Clinical Development: Frank Czerwiec
  • Senior Managing Director & Head-General Affairs: Yoshiro Matsuo
  • Director & Head-Finance: Yuko Makino

Shareholders

  • OTSUKA FAMILY /OTSUKA HOLDINGS/ (15.8%)
  • Nomura Asset Management Co., Ltd. (4.5%)
  • Otsuka Holdings Co., Ltd. (2.7%)
  • Otsuka Holdings Employee Stock Ownership Plan (2.3%)
  • The Vanguard Group, Inc. (1.9%)
  • The Awa Bank Ltd. (1.9%)
  • Daiwa Asset Management Co. Ltd. (1.7%)
  • Nikko Asset Management Co., Ltd. (1.6%)
  • BlackRock Fund Advisors (1.2%)
  • Alfresa Holdings Corp. (1.1%)

Contact Details

  • Website:http://www.otsuka.com
  • Address: Shinagawa Grand Central Tower, 12/F, 2-16-4 Konan, Tokyo, 108-8241, Japan
  • Phone: +81.3.6717.1410

Related Companies

  • Otsuka Europe Development & Commercialisation Ltd.
  • Otsuka Holdings Restricted Stock Compensation Plan
  • Otsuka Shanghai Research Institute
  • Otsuka Pharmaceutical (Switzerland) GmbH
  • Otsuka Pharmaceutical (HK) Ltd.
  • Otsuka America Foods, Inc.
  • Otsuka Pharma Scandinavia AB
  • Sichuan Otsuka Pharmaceutical Co. Ltd.
  • Otsuka (Shanghai) Foods-Safety Research & Development Co. Ltd.
  • Shanghai Otsuka Foods Co. Ltd.
  • Otsuka Pharmaceuticals (U.K.) Ltd.
  • Taiho Oncology, Inc.
  • Tianjin Otsuka Beverage Co., Ltd.
  • ReCor Medical, Inc.
  • Otsuka Medical Devices Co., Ltd.
  • Otsuka Holdingse Mployee Incentive Plan
  • Otsuka Holdings Employee Stock Ownership Plan
  • Otsuka Techno Corp.
  • Otsuka Foods Co. Ltd.
  • JIMRO Co., Ltd.
  • Nutrition & Sante' Italia SpA
  • Otsuka Pharma GmbH
  • Otsuka Packaging Ind Co. Ltd.
  • Nutrition et Sante SAS
  • Otsuka Pharmaceutical SA
  • Nardobel SAS
  • Euriso Top
  • Nutrition et Soja
  • Nutrition & Sante Iberia SL
  • JO Pharma KK

Competitors

  • JW Holdings Corporation
  • Kura Oncology, Inc.
  • BridgeBio Pharma, Inc.
  • Intra-Cellular Therapies, Inc.
  • DURECT Corporation
  • Oasmia Pharmaceutical AB
  • Church & Dwight Co., Inc.
  • BioLineRX Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Alkermes Plc
  • Exalenz Bioscience Ltd
  • Univo Pharmaceuticals Ltd.
  • Minerva Neurosciences Inc
  • VistaGen Therapeutics, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • Axsome Therapeutics, Inc.
  • Onconova Therapeutics Inc.
  • ACADIA Pharmaceuticals Inc.
  • Adamas Pharmaceuticals, Inc.
  • Pieris Pharmaceuticals, Inc.
  • Aptinyx Inc
  • SELLAS Life Sciences Group, Inc.
  • Syros Pharmaceuticals, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Aduro BioTech, Inc.
  • ArQule, Inc.
  • Concert Pharmaceuticals, Inc.
  • Qurient Co., Ltd.
  • Humanigen Inc
Last Updated on 23 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media